论文部分内容阅读
目的：探讨炎症性肠病临床治疗中采用益生菌与美沙拉嗪联合治疗的效果。方法：选取我院在2013年4月至2014年4月收治的炎症性肠病患者88例，将其随机分为观察组和对照组各44例。两组患者均给予常规性抗炎治疗，其中对照组在此基础上单纯采用美沙拉嗪，观察组采用益生菌与美沙拉嗪联合治疗，对两组患者治疗28d之后，观察统计两组临床治疗效果与不良反应发生率。结果：观察组总有效率远高于对照组总有效率，不良反应发生率远低于对照组。结论：采用益生菌与美沙拉嗪联合治疗炎症性肠病的临床效果良好，值得在临床中推广使用。“,”Objective: To investigate the clinical treatment of inflammatory bowel disease with combination therapy using the probiotic effect of mesalazine. Methods: Patients with inflammatory bowel disease in our hospital from April 2013 to April 2014 were treated 88 cases were randomly divided into two groups and the control group 44 cases. Al patients were treated with conventional anti-inflammatory treatment, the control group on the basis of only using mesalamine, observation group probiotics and combination therapy mesalazine, two groups of patients after 28d, the two groups were observed in clinical treatment statistics the incidence of adverse effects. Results: The total effective rate is much higher than the total efficiency, adverse reaction rates far lower than the control group. Conclusion: The use of probiotics combined with mesalazine therapy of inflammatory bowel disease clinical effect is good and should be introduced in the clinic.